|
1
|
Raguz S and Yagüe E: Resistance to
chemotherapy: New treatments and novel insights into an old
problem. Br J Cancer. 99:387–391. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gillet JP and Gottesman MM: Overcoming
multidrug resistance in cancer: 35 years after the discovery of
ABCB1. Drug Resist Updat. 15:2–4. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Steinbach D and Legrand O: ABC
transporters and drug resistance in leukemia: Was P-gp nothing but
the first head of the Hydra? Leukemia. 21:1172–1176. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Trock BJ, Leonessa F and Clarke R:
Multidrug resistance in breast cancer: A meta-analysis of
MDR1/gp170 expression and its possible functional significance. J
Natl Cancer Inst. 89:917–931. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Clarke R, Leonessa F and Trock B:
Multidrug resistance/P-glycoprotein and breast cancer: Review and
meta-analysis. Semin Oncol. 32(Suppl 7): S9–S15. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Reinhart BJ, Slack FJ, Basson M,
Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G:
The 21-nucleotide let-7 RNA regulates developmental timing in
Caenorhabditis elegans. Nature. 403:901–906. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Negrini M and Calin GA: Breast cancer
metastasis: A microRNA story. Breast Cancer Res. 10:2032008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jang JS, Jeon HS, Sun Z, Aubry MC, Tang H,
Park CH, Rakhshan F, Schultz DA, Kolbert CP, Lupu R, et al:
Increased miR-708 expression in NSCLC and its association with poor
survival in lung adenocarcinoma from never smokers. Clin Cancer
Res. 18:3658–3667. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang H, Kong W, He L, Zhao JJ, O'Donnell
JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al:
MicroRNA expression profiling in human ovarian cancer: miR-214
induces cell survival and cisplatin resistance by targeting PTEN.
Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi
Y, Xiong W, Li G, Lu J, Fodstad O, et al: MicroRNA-125b confers the
resistance of breast cancer cells to paclitaxel through suppression
of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J
Biol Chem. 285:21496–21507. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miller TE, Ghoshal K, Ramaswamy B, Roy S,
Datta J, Shapiro CL, Jacob S and Majumder S: MicroRNA-221/222
confers tamoxifen resistance in breast cancer by targeting p27Kip1.
J Biol Chem. 283:29897–29903. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Poliseno L, Salmena L, Riccardi L, Fornari
A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A and Fedele G:
Identification of the miR-106b~25 microRNA cluster as a
proto-oncogenic PTEN-targeting intron that cooperates with its host
gene MCM7 in transformation. Sci Signal. 3:ra292010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Petrocca F, Visone R, Onelli MR, Shah MH,
Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini
M, et al: E2F1-regulated microRNAs impair TGFbeta-dependent
cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell.
13:272–286. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Acosta JC and Gil J: Senescence: A new
weapon for cancer therapy. Trends Cell Biol. 22:211–219. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou Y, Hu Y, Yang M, Jat P, Li K,
Lombardo Y, Xiong D, Coombes RC, Raguz S and Yagüe E: The
miR-106b~25 cluster promotes bypass of doxorubicin-induced
senescence and increase in motility and invasion by targeting the
E-cadherin transcriptional activator EP300. Cell Death Differ.
21:462–474. 2014. View Article : Google Scholar :
|
|
18
|
Zhao JJ, Gjoerup OV, Subramanian RR, Cheng
Y, Chen W, Roberts TM and Hahn WC: Human mammary epithelial cell
transformation through the activation of phosphatidylinositol
3-kinase. Cancer Cell. 3:483–495. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Unsworth H, Raguz S, Edwards HJ, Higgins
CF and Yagüe E: mRNA escape from stress granule sequestration is
dictated by localization to the endoplasmic reticulum. FASEB J.
24:3370–3380. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee JS, Paull K, Alvarez M, Hose C, Monks
A, Grever M, Fojo AT and Bates SE: Rhodamine efflux patterns
predict P-glycoprotein substrates in the National Cancer Institute
drug screen. Mol Pharmacol. 46:627–638. 1994.PubMed/NCBI
|
|
21
|
Yagüe E, Arance A, Kubitza L, O'Hare M,
Jat P, Ogilvie CM, Hart IR, Higgins CF and Raguz S: Ability to
acquire drug resistance arises early during the tumorigenesis
process. Cancer Res. 67:1130–1137. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yague E, Armesilla AL, Harrison G, Elliott
J, Sardini A, Higgins CF and Raguz S: P-glycoprotein (MDR1)
expression in leukemic cells is regulated at two distinct steps,
mRNA stabilization and translational initiation. J Biol Chem.
278:10344–10352. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Raguz S, Adams C, Masrour N, Rasul S,
Papoutsoglou P, Hu Y, Cazzanelli G, Zhou Y, Patel N, Coombes C, et
al: Loss of O6-methylguanine-DNA methyltransferase
confers collateral sensitivity to carmustine in topoisomerase
II-mediated doxo-rubicin resistant triple negative breast cancer
cells. Biochem Pharmacol. 85:186–196. 2013. View Article : Google Scholar
|
|
24
|
Vichai V and Kirtikara K: Sulforhodamine B
colorimetric assay for cytotoxicity screening. Nat Protoc.
1:1112–1116. 2006. View Article : Google Scholar
|
|
25
|
Hu Y, Cheng X, Li S, Zhou Y, Wang J, Cheng
T, Yang M and Xiong D: Inhibition of sorcin reverses multidrug
resistance of K562/A02 cells and MCF-7/A02 cells via regulating
apoptosis-related proteins. Cancer Chemother Pharmacol. 72:789–798.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rasul S, Balasubramanian R, Filipović A,
Slade MJ, Yagüe E and Coombes RC: Inhibition of gamma-secretase
induces G2/M arrest and triggers apoptosis in breast cancer cells.
Br J Cancer. 100:1879–1888. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nitiss JL: Targeting DNA topoisomerase II
in cancer chemotherapy. Nat Rev Cancer. 9:338–350. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ewald JA, Desotelle JA, Wilding G and
Jarrard DF: Therapy-induced senescence in cancer. J Natl Cancer
Inst. 102:1536–1546. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McGrogan BT, Gilmartin B, Carney DN and
McCann A: Taxanes, microtubules and chemoresistant breast cancer.
Biochim Biophys Acta. 1785:96–132. 2008.
|
|
30
|
Wu CP, Hsieh CH and Wu YS: The emergence
of drug transporter-mediated multidrug resistance to cancer
chemotherapy. Mol Pharm. 8:1996–2011. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Friedrich K, Wieder T, Von Haefen C,
Radetzki S, Jänicke R, Schulze-Osthoff K, Dörken B and Daniel PT:
Overexpression of caspase-3 restores sensitivity for drug-induced
apoptosis in breast cancer cell lines with acquired drug
resistance. Oncogene. 20:2749–2760. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kathawala RJ, Gupta P, Ashby CR Jr and
Chen ZS: The modulation of ABC transporter-mediated multidrug
resistance in cancer: A review of the past decade. Drug Resist
Updat. 18:1–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
May CD, Sphyris N, Evans KW, Werden SJ,
Guo W and Mani SA: Epithelial-mesenchymal transition and cancer
stem cells: A dangerously dynamic duo in breast cancer progression.
Breast Cancer Res. 13:2022011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Korpal M, Lee ES, Hu G and Kang Y: The
miR-200 family inhibits epithelial-mesenchymal transition and
cancer cell migration by direct targeting of E-cadherin
transcriptional repressors ZEB1 and ZEB2. J Biol Chem.
283:14910–14914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ferreira P, Oliveira MJ, Beraldi E, Mateus
AR, Nakajima T, Gleave M, Yokota J, Carneiro F, Huntsman D, Seruca
R, et al: Loss of functional E-cadherin renders cells more
resistant to the apoptotic agent taxol in vitro. Exp Cell Res.
310:99–104. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shiota M, Yokomizo A, Kashiwagi E, Tada Y,
Inokuchi J, Tatsugami K, Kuroiwa K, Uchiumi T, Seki N and Naito S:
Foxo3a expression and acetylation regulate cancer cell growth and
sensitivity to cisplatin. Cancer Sci. 101:1177–1185. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Takeuchi A, Shiota M, Tatsugami K,
Yokomizo A, Tanaka S, Kuroiwa K, Eto M and Naito S: p300 mediates
cellular resistance to doxorubicin in bladder cancer. Mol Med Rep.
5:173–176. 2012.
|
|
40
|
Mees ST, Mardin WA, Wendel C, Baeumer N,
Willscher E, Senninger N, Schleicher C, Colombo-Benkmann M and
Haier J: EP300 - a miRNA-regulated metastasis suppressor gene in
ductal adenocarcinomas of the pancreas. Int J Cancer. 126:114–124.
2010. View Article : Google Scholar
|
|
41
|
Callaghan R, Luk F and Bebawy M:
Inhibition of the multidrug resistance P-glycoprotein: Time for a
change of strategy? Drug Metab Dispos. 42:623–631. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chekhun VF, Lukyanova NY, Kovalchuk O,
Tryndyak VP and Pogribny IP: Epigenetic profiling of
multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals
novel hyper- and hypomethylated targets. Mol Cancer Ther.
6:1089–1098. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lu L, Zhou D, Jiang X, Song K, Li K and
Ding W: Loss of E-cadherin in multidrug resistant breast cancer
cell line MCF-7/Adr: Possible implication in the enhanced invasive
ability. Eur Rev Med Pharmacol Sci. 16:1271–1279. 2012.PubMed/NCBI
|
|
44
|
Doyle L and Ross DD: Multidrug resistance
mediated by the breast cancer resistance protein BCRP (ABCG2).
Oncogene. 22:7340–7358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sprowl JA, Reed K, Armstrong SR, Lanner C,
Guo B, Kalatskaya I, Stein L, Hembruff SL, Tam A and Parissenti AM:
Alterations in tumor necrosis factor signaling pathways are
associated with cytotoxicity and resistance to taxanes: A study in
isogenic resistant tumor cells. Breast Cancer Res. 14:R22012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Park SJ, Wu CH, Gordon JD, Zhong X, Emami
A and Safa AR: Taxol induces caspase-10-dependent apoptosis. J Biol
Chem. 279:51057–51067. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Janssen K, Pohlmann S, Jänicke RU,
Schulze-Osthoff K and Fischer U: Apaf-1 and caspase-9 deficiency
prevents apoptosis in a Bax-controlled pathway and promotes
clonogenic survival during paclitaxel treatment. Blood.
110:3662–3672. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jelínek M, Balušíková K, Kopperová D,
Nĕmcová-Fürstová V, Šrámek J, Fidlerová J, Zanardi I, Ojima I and
Kovář J: Caspase-2 is involved in cell death induction by taxanes
in breast cancer cells. Cancer Cell Int. 13:422013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yamakawa N, Takahashi A, Mori E, Imai Y,
Furusawa Y, Ohnishi K, Kirita T and Ohnishi T: High LET radiation
enhances apoptosis in mutated p53 cancer cells through caspase-9
activation. Cancer Sci. 99:1455–1460. 2008. View Article : Google Scholar : PubMed/NCBI
|
